ImmunityBio, Inc. IBRX Reportable Segment — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s reportable segment — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s reportable segment — net loss?
- ImmunityBio, Inc. (IBRX) reported reportable segment — net loss of -$632.8M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — net loss changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — net loss decreased by 388.0% year-over-year, from -$129.67M to -$632.8M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — net loss?
- Over 3 years (2022 to 2025), ImmunityBio, Inc.'s reportable segment — net loss has grown at a -5.6% compound annual growth rate (CAGR), from -$417.32M to -$351.47M.
- What does reportable segment — net loss mean?
- The final net loss recorded by a specific business segment after all costs and taxes.
- How do you interpret reportable segment — net loss?
- A narrowing net loss suggests the segment is moving closer to commercial viability or cost optimization, whereas a widening loss indicates increased investment or operational challenges.
- How does reportable segment — net loss compare across companies?
- Commonly reported by biotech firms to show the financial impact of specific drug development programs or therapeutic platforms.